Media: Investors: Gabby Tarbert (224) 244-0111 [email protected] Liz Shea (847) 935-2211 [email protected] SOURCE AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more inform ...

– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring m ...

Core Insights - Veeva Systems has announced that Novo Nordisk's International Operations business unit will implement Veeva Vault CRM to enhance its commercial capabilities with advanced AI technology [1][2][3] Group 1: Partnership and Technology - The partnership between Veeva and Novo Nordisk aims to leverage AI-driven technology to improve the delivery of innovative medicines for chronic diseases [2] - Vault CRM is designed to support effective commercial execution across both personal and digital channels, addressing specific business and compliance needs in various countries [2][3] Group 2: Company Overview - Veeva Systems provides cloud-based solutions for the life sciences industry, serving over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [4] - The company is committed to innovation and balancing the interests of all stakeholders, including customers, employees, and shareholders [4]

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bora Pharmaceuticals Co., Ltd. ((TWSE: 6472, OTCQX:BORAY), a premier international contract development and manufacturing organization and specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market.Bora Pharmaceuticals Co., Ltd. begins trading today on OTCQX under the symbol "BORAY." U.S. investors can fin ...

REHOVOT, Israel and BOSTON, January 7, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicineâ"¢ platform. This partnership aims to accelerate the discov ...

- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company’s first-in-class menin inhibitor, Revuforj® (revume ...

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a premier international contract development and manufacturing organization and specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market. Bora Pharmaceuticals Co., Ltd. begins trading today on OTCQX under the symbol “BORAY.” U.S. investors can f ...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEXâ"¢ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). This randomi ...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEXâ"¢ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). This randomi ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT. ...